Kymera Therapeutics Inc
KYMR77.810USD
-0.310-0.40%
Close 12/31, 16:00（ET）Quotes delayed by 15 min
5.58BMarket Cap
LossP/E TTM
More Details of Kymera Therapeutics Inc Company
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.
Kymera Therapeutics Inc Info
Ticker SymbolKYMR
Company nameKymera Therapeutics Inc
IPO dateAug 21, 2020
CEOMainolfi (Nello)
Number of employees188
Security typeOrdinary Share
Fiscal year-endAug 21
Address500 North Beacon Street, 4Th Floor
CityWATERTOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02472
Phone18572855314
Websitehttps://www.kymeratx.com/
Ticker SymbolKYMR
IPO dateAug 21, 2020
CEOMainolfi (Nello)
Company Executives of Kymera Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Nello Mainolfi, Ph.D.
Dr. Nello Mainolfi, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
659.96K
--
Dr. Jared August Gollob, M.D.
Dr. Jared August Gollob, M.D.
Chief Medical Officer
Chief Medical Officer
57.49K
--
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
52.50K
--
Mr. Noah Goodman
Mr. Noah Goodman
Chief Business Officer
Chief Business Officer
50.08K
--
Dr. Jeremy G. Chadwick, Ph.D.
Dr. Jeremy G. Chadwick, Ph.D.
Chief Operating Officer
Chief Operating Officer
15.80K
-14.01%
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Justine Koenigsberg
Ms. Justine Koenigsberg
Vice President - Investor Relations
Vice President - Investor Relations
--
--
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Independent Director
Independent Director
--
--
Dr. Bruce L. Booth
Dr. Bruce L. Booth
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
--
--
Dr. Gorjan Hrustanovic, Ph.D.
Dr. Gorjan Hrustanovic, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Nello Mainolfi, Ph.D.
Dr. Nello Mainolfi, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
659.96K
--
Dr. Jared August Gollob, M.D.
Dr. Jared August Gollob, M.D.
Chief Medical Officer
Chief Medical Officer
57.49K
--
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
52.50K
--
Mr. Noah Goodman
Mr. Noah Goodman
Chief Business Officer
Chief Business Officer
50.08K
--
Dr. Jeremy G. Chadwick, Ph.D.
Dr. Jeremy G. Chadwick, Ph.D.
Chief Operating Officer
Chief Operating Officer
15.80K
-14.01%
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2024
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
47.07M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 30
Updated: Sun, Nov 30
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
13.36%
Avoro Capital Advisors LLC
7.96%
Fidelity Management & Research Company LLC
7.37%
BVF Partners L.P.
6.90%
The Vanguard Group, Inc.
6.78%
Other
57.63%
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
13.36%
Avoro Capital Advisors LLC
7.96%
Fidelity Management & Research Company LLC
7.37%
BVF Partners L.P.
6.90%
The Vanguard Group, Inc.
6.78%
Other
57.63%
Shareholder Types
Shareholders
Proportion
Investment Advisor
40.05%
Hedge Fund
28.83%
Investment Advisor/Hedge Fund
28.22%
Venture Capital
7.47%
Individual Investor
1.29%
Research Firm
1.28%
Corporation
0.97%
Private Equity
0.51%
Bank and Trust
0.39%
Institutional Shareholding
Updated: 4 hours ago
Updated: 4 hours ago
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
446
85.54M
107.20%
+2.78M
2025Q3
423
80.49M
111.88%
+1.59M
2025Q2
394
76.16M
108.56%
+417.04K
2025Q1
408
74.79M
106.76%
-4.90M
2024Q4
392
73.17M
112.73%
-3.17M
2024Q3
379
71.17M
110.57%
-5.78M
2024Q2
360
69.86M
113.52%
-7.55M
2024Q1
364
70.22M
115.13%
-982.70K
2023Q4
350
63.05M
113.62%
-5.46M
2023Q3
341
59.94M
108.11%
-9.64M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Baker Bros. Advisors LP
10.66M
13.36%
+4.01M
+60.31%
Dec 11, 2025
Avoro Capital Advisors LLC
6.35M
7.96%
-205.56K
-3.14%
Sep 30, 2025
Fidelity Management & Research Company LLC
5.88M
7.37%
+447.08K
+8.23%
Sep 30, 2025
BVF Partners L.P.
5.50M
6.9%
--
--
Dec 11, 2025
The Vanguard Group, Inc.
5.41M
6.78%
-198.13K
-3.53%
Sep 30, 2025
Wellington Management Company, LLP
5.20M
6.51%
-176.37K
-3.28%
Sep 30, 2025
T. Rowe Price Associates, Inc.
5.04M
6.31%
-1.77M
-25.96%
Sep 30, 2025
Atlas Venture
4.90M
6.14%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.72M
4.67%
+205.15K
+5.83%
Sep 30, 2025
Invus Public Equities Advisors, LLC
3.43M
4.3%
--
--
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Clough Hedged Equity ETF
2.42%
Invesco Dorsey Wright Healthcare Momentum ETF
1.41%
Harbor Human Capital Factor US Small Cap ETF
1.31%
State Street SPDR S&P Biotech ETF
1.27%
Virtus LifeSci Biotech Clinical Trials ETF
0.89%
Direxion Daily S&P Biotech Bull 3X Shares
0.63%
First Trust Multi-Manager Small Cap Opportunities ETF
0.61%
ProShares Ultra Nasdaq Biotechnology
0.59%
Invesco Nasdaq Biotechnology ETF
0.43%
First Trust Small Cap Growth AlphaDEX Fund
0.35%
View more
Clough Hedged Equity ETF
Proportion2.42%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.41%
Harbor Human Capital Factor US Small Cap ETF
Proportion1.31%
State Street SPDR S&P Biotech ETF
Proportion1.27%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.89%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.63%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.61%
ProShares Ultra Nasdaq Biotechnology
Proportion0.59%
Invesco Nasdaq Biotechnology ETF
Proportion0.43%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.35%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Kymera Therapeutics Inc?
The top five shareholders of Kymera Therapeutics Inc are:
Baker Bros. Advisors LP holds 10.66M shares, accounting for 13.36% of the total shares.
Avoro Capital Advisors LLC holds 6.35M shares, accounting for 7.96% of the total shares.
Fidelity Management & Research Company LLC holds 5.88M shares, accounting for 7.37% of the total shares.
BVF Partners L.P. holds 5.50M shares, accounting for 6.90% of the total shares.
The Vanguard Group, Inc. holds 5.41M shares, accounting for 6.78% of the total shares.
Baker Bros. Advisors LP holds 10.66M shares, accounting for 13.36% of the total shares.
Avoro Capital Advisors LLC holds 6.35M shares, accounting for 7.96% of the total shares.
Fidelity Management & Research Company LLC holds 5.88M shares, accounting for 7.37% of the total shares.
BVF Partners L.P. holds 5.50M shares, accounting for 6.90% of the total shares.
The Vanguard Group, Inc. holds 5.41M shares, accounting for 6.78% of the total shares.
What are the top three shareholder types of Kymera Therapeutics Inc?
The top three shareholder types of Kymera Therapeutics Inc are:
Baker Bros. Advisors LP
Avoro Capital Advisors LLC
Fidelity Management & Research Company LLC
Baker Bros. Advisors LP
Avoro Capital Advisors LLC
Fidelity Management & Research Company LLC
How many institutions hold shares of Kymera Therapeutics Inc (KYMR)?
As of 2025Q4, 446 institutions hold shares of Kymera Therapeutics Inc, with a combined market value of approximately 85.54M, accounting for 107.20% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -4.68%.
What is the biggest source of revenue for Kymera Therapeutics Inc?
In FY2024, the -- business generated the highest revenue for Kymera Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
